...
首页> 外文期刊>The Medical Clinics of North America >The use of anti-IgE in the treatment of allergic asthma.
【24h】

The use of anti-IgE in the treatment of allergic asthma.

机译:抗IgE在过敏性哮喘治疗中的用途。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Allergic sensitization plays a significant role in the development of asthma in many patients. IgE-mediated immune responses play a central role in the pathogenesis of this condition. The development of a treatment that interrupts this pathway is particularly desirable to prevent downstream events. Large-scale trials in patients ranging in age from 6 to 76 years have shown that omalizumab therapy is safe and effective in the treatment of severe allergic asthma. This is particularly true in patients who experience poor disease control despite high doses of inhaled steroids or need oral steroids for control of their disease. These patients are at risk for severe exacerbations despite recommended therapy, and anti-IgE therapy has proved to reduce these episodes. Early aggressive therapy of asthma is needed for maximum control in all age groups. Despite the efficacy of inhaled steroids there is a reluctance to use these agents, especially in younger children. Because of these concerns a long-acting treatment is especially desirable. Because of imperfect effort or technique limiting inhaled medications, introduction of an effective agent that could be administered parenterally at long intervals also is very important. Allergic rhinitis is a co-existing problem in many patients with allergic asthma. Immunotherapy trials have suggested that early intervention with immunotherapy and allergic rhinitis patients may actually prevent the development of asthma. Early treatment of patients with anti-IgE may also have benefits, particularly in those who have concomitant allergic rhinitis in addition to allergic asthma. Although omalizumab has not yet received Food and Drug Administration approval in the United States, it shows great promise in the management of patients requiring high doses of inhaled or oral corticosteroids for control of their disease and to prevent exacerbations of asthma in such patients. Reductions in high doses of inhaled or oral corticosteroids may prevent long-term complications of these treatments.
机译:过敏性致敏在许多患者的哮喘发展中起重要作用。 IgE介导的免疫反应在这种疾病的发病机理中起着核心作用。为了防止下游事件,特别需要开发一种中断该途径的治疗方法。在6至76岁的患者中进行的大规模试验表明,奥马珠单抗治疗严重的过敏性哮喘是安全有效的。对于尽管吸入糖皮质激素高剂量但仍无法控制疾病的患者或需要口服类固醇来控制其疾病的患者尤其如此。尽管推荐了治疗方法,但这些患者仍存在严重病情加重的风险,并且抗IgE治疗已被证明可以减少这些发作。为了尽早控制所有年龄段的人群,需要早期积极治疗哮喘。尽管吸入类固醇有效,但仍不愿使用这些药物,尤其是在年幼的儿童中。由于这些问题,特别需要长效治疗。由于不完善的努力或限制吸入药物的技术,因此引入可以长时间间隔胃肠外给药的有效药物也非常重要。在许多过敏性哮喘患者中,过敏性鼻炎是一个并存的问题。免疫疗法试验表明,对免疫疗法和过敏性鼻炎患者进行早期干预实际上可以预防哮喘的发展。抗IgE患者的早期治疗也可能有益处,特别是在那些除了过敏性哮喘之外还伴有过敏性鼻炎的患者中。尽管奥马珠单抗尚未在美国获得食品药品监督管理局的批准,但它在治疗需要大剂量吸入或口服皮质类固醇以控制其疾病并预防此类患者的哮喘恶化的患者中显示出巨大的希望。减少大剂量吸入或口服皮质类固醇激素可以预防这些治疗的长期并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号